San Juan City

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Triple-negative breast cancer3 trials
• Metastatic breast cancer2 trials
• Prostate cancer1 trial

Phase

• Phase 38 trials
• Phase 11 trial

Status

• Active, not recruiting7 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca9 trials

Running trials

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06417814· Phase 3· AstraZeneca· Source

• Recruiting

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Breast Cancer Study Locator Service

• Active, not recruiting

  Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  NCT05261399· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

  NCT05374512· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

  NCT03706690· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Triple-negative breast cancer1 recruiting

Closed trials

• Recruiting

  Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

  NCT04686305· Phase 1· AstraZeneca· Source

  Contact: AstraZeneca Lung Cancer Study Locator Service